Welcome to our dedicated page for HealWELL AI news (Ticker: HWAIF), a resource for investors and traders seeking the latest updates and insights on HealWELL AI stock.
HealWELL AI Inc. (HWAIF) is a leader in AI-powered healthcare solutions focused on improving preventative care through advanced clinical decision support systems. This page serves as the definitive source for official company updates, providing stakeholders with timely insights into strategic developments shaping the future of medical technology.
Investors and industry professionals will find curated press releases covering earnings announcements, strategic partnerships, and technology advancements. Our repository includes updates on regulatory milestones, research collaborations, and AI-driven product innovations that enhance early disease detection capabilities.
All content is rigorously verified to ensure accuracy and relevance for financial analysis and market research. Bookmark this page for direct access to HWAIF's latest progress in transforming healthcare through artificial intelligence and data science applications.
HEALWELL AI's subsidiary, Pentavere, announces a partnership with Takeda to enhance real-world evidence analysis for patients with hereditary angioedema (HAE) having normal C1 inhibitor. This collaboration has generated one of the largest global datasets for HAE patients, aiming to improve clinical outcomes. The initiative builds on Pentavere's win in the Takeda Canada Innovation Challenge 2022. The Canadian Organization of Rare Disorders praises this partnership for its potential to revolutionize rare disease diagnosis and care in Canada. A manuscript and an abstract on the dataset are in preparation for publication.
HEALWELL AI has appointed Anthony Lam as its new Chief Financial Officer (CFO), effective immediately. Lam brings over 20 years of senior finance and operational leadership experience in various technology sectors and will report directly to CEO Dr. Alexander Dobranowski.
Lam succeeds Scott Nirenberski, who served as CFO since September 2020. Lam's previous roles include CFO at eSentire and Newtopia, with a background in analytics, treasury, and capital markets.
Dr. Dobranowski expressed confidence in Lam's ability to drive HEALWELL's next growth phase. Lam aims to enhance financial discipline and leverage technology for efficiency. The company focuses on preventative care using AI and data science.
HEALWELL AI, trading under the symbol HWAIF, announced a partnership between its subsidiary Pentavere and Sunnybrook Health Sciences Centre, led by Dr. Tony Eskander, to enhance cancer staging using the DARWEN™ AI platform.
This collaboration demonstrated the AI's capability to improve the accuracy and speed of cancer staging, which is important for head and neck cancers, and was published in JAMA Otolaryngology.
The study showcased AI's potential to analyze unstructured clinical text within electronic health records, supporting clinical decision-making and improving patient outcomes.
The findings suggest that Pentavere's AI could revolutionize oncological care by providing clinicians with timely and accurate cancer staging, thus optimizing treatment decisions.
HEALWELL AI announced its participation in leading-edge research on Chronic Kidney Disease (CKD). Their Clinical Co-Pilot technology, integrated with a machine model for CKD progression, enhances guideline-recommended testing when paired with EHR-linked clinical decision support. An abstract co-authored by HEALWELL's subsidiary, Khure Health, was published in the American Journal of Kidney Diseases. The research highlights the utility of HEALWELL’s AI technology in improving CKD patient care. CKD is a significant health issue, affecting one-seventh of the North American population and costing Canada over $40 billion annually. Recently, WELL Health Technologies launched its second-generation AI Co-Pilot, powered by HEALWELL, now available to thousands of providers.
HEALWELL AI reported significant growth in Q1-2024, with revenue from continuing operations reaching $4.58 million, a 132% increase compared to $1.97 million in Q1-2023.
This growth is primarily attributed to the acquisition of Intrahealth on February 1, 2024. The company’s revenue run-rate has more than doubled to over $20 million, with SaaS and services forming the largest component.
The management projects potential to more than double the annual revenue to over $40 million with existing cash reserves. HEALWELL closed Q1-2024 with $11.3 million in cash, and an additional $20 million financing deal is expected to further strengthen its financial position.
Despite positive revenue growth, the company posted an adjusted EBITDA loss of $2.56 million. HEALWELL’s strategic alliance with WELL Health Technologies continues to flourish with new AI-driven tools for chronic disease detection.
HEALWELL AI Inc. will announce its Fiscal First Quarter 2024 financial results on May 14, 2024. The company focuses on preventative care and will hold a conference call and webcast to discuss the results, hosted by CEO Dr. Alexander Dobranowski and CFO Scott Nirenberski.
WELL and HEALWELL AI have launched the second-generation WELL AI Decision Support (WAIDS) with advanced chronic disease screening capabilities, aiding in patient risk stratification. The tool identifies over 100 diseases, providing actionable insights at the point of care. Chronic diseases affect 45.1% of Canadians, costing the economy $190 billion annually.
FAQ
What is the current stock price of HealWELL AI (HWAIF)?
What is the market cap of HealWELL AI (HWAIF)?
